Showing results (431-440 of 538) with videos related to

Sort By:
Pageof 54
European Journal of Neurology|July 29, 2023
European Academy of Neurology guidelines on the treatment of cluster headacheArne May, Stefan Evers, Peter J Goadsby, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|December 12, 2018
Cortical abnormalities in episodic migraine: A multi-center 3T MRI studyStefano Magon, Arne May, Anne Stankewitz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 30, 2021
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY studyMichel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
The New England Journal of Medicine|November 25, 2017
Fremanezumab for the Preventive Treatment of Chronic MigraineStephen D Silberstein, David W Dodick, Marcelo E Bigal, et al.
Orthopaedic Journal of Sports Medicine|August 26, 2021
Reduction in Diameter of Hamstring Autograft With Additional Circumferential Preconditioning During ACL Reconstruction in a Pediatric PopulationDaniel Weltsch, Calvin Chan, Kevin M Dale, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 9, 2015
Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 TeslaStefano Magon, Arne May, Anne Stankewitz, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
The New England Journal of Medicine|July 11, 2019
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for MigraineRichard B Lipton, Robert Croop, Elyse G Stock, et al.
Pageof 54